Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia
Expert Rev Hematol. 2024 Apr 23. doi: 10.1080/17474086.2024.2347303. Online ahead of print.NO ABSTRACTPMID:38654593 | DOI:10.1080/17474086.2024.2347303 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - April 24, 2024 Category: Hematology Authors: H åkon Reikvam Richard Dillon Source Type: research
GSE239307 Inflammatory conversion of normal hematopoietic stem and progenitor cells by acute myeloid leukemia derived extracellular vesicles in vivo
Contributors : Ding-Wen Chen ; Julie M Schrey ; Jian-Meng Fan ; Dana V Mitchell ; Deanne M Taylor ; Peter KurreSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusInflammation in the bone marrow (BM) microenvironment is a constitutive component of acute myeloid leukemia (AML) pathogenesis. Studies have demonstrated that leukemic blasts propagate acute inflammation in the AML niche. Our recent studies in a congenic AML model suggest residual healthy hematopoietic stem and progenitor cells (HSPCs) participate in the inflammatory crosstalk. However, the underlying mechanism that drives th...
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Work Disability and Return to Work After Treatment for Acute Lymphoblastic Leukemia: A Danish Nationwide Cohort Study [Letter]
(Source: Clinical Epidemiology)
Source: Clinical Epidemiology - April 24, 2024 Category: Epidemiology Tags: Clinical Epidemiology Source Type: research
Role of the STING pathway in myeloid neoplasms: a prospero-registered systematic review of principal hurdles of STING on the road to the clinical practice
AbstractMyeloid neoplasms are a group of bone marrow diseases distinguished by disruptions in the molecular pathways that regulate the balance between hematopoietic stem cell (HSC) self-renewal and the generation of specialized cells. Cytokines and chemokines, two important components of the inflammatory process, also influence hematological differentiation. In this scenario, immunological dysregulation plays a pivotal role in the pathogenesis of bone marrow neoplasms. The STING pathway recognizes DNA fragments in the cell cytoplasm and triggers an immune response by type I interferons. The role of STING in cancer has not ...
Source: Medical Oncology - April 24, 2024 Category: Cancer & Oncology Source Type: research
Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia
Blood Cancer Journal, Published online: 24 April 2024; doi:10.1038/s41408-024-01055-1Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 24, 2024 Category: Hematology Authors: Cheng Wang Jianfeng Li Weiyang Liu Lingling Zhao Han Yan Yuchen Yan Jiayi Ren Lijun Peng Jiaojiao Zhang Yuanfang Liu Xiangqin Weng Yongmei Zhu Duohui Jing Jian-Qing Mi Jin Wang Source Type: research
Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF- κB inhibition and the induction of oxidative stress
J Cell Mol Med. 2024 Apr;28(8):e18333. doi: 10.1111/jcmm.18333.ABSTRACTAcute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a...
Source: Molecular Medicine - April 23, 2024 Category: Molecular Biology Authors: Rafaela G A Costa Maiara de S Oliveira Ana Carolina B da C Rodrigues Suellen L R Silva Ingrid R S B Dias Milena B P Soares Ludmila de Faro Valverde Clarissa Araujo Gurgel Rocha Rosane Borges Dias Daniel P Bezerra Source Type: research
Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF- κB inhibition and the induction of oxidative stress
J Cell Mol Med. 2024 Apr;28(8):e18333. doi: 10.1111/jcmm.18333.ABSTRACTAcute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a...
Source: J Cell Mol Med - April 23, 2024 Category: Molecular Biology Authors: Rafaela G A Costa Maiara de S Oliveira Ana Carolina B da C Rodrigues Suellen L R Silva Ingrid R S B Dias Milena B P Soares Ludmila de Faro Valverde Clarissa Araujo Gurgel Rocha Rosane Borges Dias Daniel P Bezerra Source Type: research
Exercise and QUality diet After Leukemia (EQUAL): A randomized weight loss trial among adult survivors of childhood leukemia in the Childhood Cancer Survivor Study
CONCLUSIONS: A remote weight-loss intervention that was successful among adults with CV conditions did not result in significant weight loss among adult survivors of childhood ALL.IMPACT: Future interventions in this population must be tailored to the unique needs of survivors to encourage engagement and adherence.PMID:38652494 | DOI:10.1158/1055-9965.EPI-23-1601 (Source: Cancer Control)
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: Danielle Novetsky Friedman Joanne F Chou Jeanne M Clark Chaya S Moskowitz Jennifer S Ford Gregory T Armstrong Nidha Z Mubdi Aaron McDonald Paul C Nathan Charles A Sklar Lakshmi V Ramanathan Leslie L Robison Kevin C Oeffinger Emily S Tonorezos Source Type: research
FLT3 agonists and secondary hematopoietic malignancies: a potential class effect
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non ‐high‐risk acute lymphoblastic leukemia treated according to the ALL‐MB 2008 protocol
ConclusionOur data show that combining clinical risk factors with MFC-MRD measurement is the most useful tool for risk group stratification of children with BCP-ALL in the reduced-intensity protocols. However, this algorithm can be supplemented with cytogenetic data for part of the ImR group. (Source: Cancer Medicine)
Source: Cancer Medicine - April 23, 2024 Category: Cancer & Oncology Authors: Alexander Popov,
Guenter Henze,
Grigory Tsaur,
Oleg Budanov,
Julia Roumiantseva,
Mikhail Belevtsev,
Tatiana Verzhbitskaya,
Liudmila Movchan,
Svetlana Lagoyko,
Liudmila Zharikova,
Yulia Olshanskaya,
Tatiana Riger,
Alena Valochnik,
Natalia Miak Tags: RESEARCH ARTICLE Source Type: research
GSE224813 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [CUT & TAG]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex c...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
GSE239350 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq 2]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex ...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Mus musculus Source Type: research
GSE224815 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia [RNA-seq]
Contributors : Xuelan Chen ; Qi Zhang ; Chong Chen ; Yu LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAcute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia, that is generally driven by PML-RARA, resulting from a balanced chromosomal translocation t(15;17) (q24.1;q21.2). However, approximately 2% of APL patients carry other variants of RARA-fusions, which pose challenges for diagnosis and treatment. Here, we report a novel t(14;17) translocation in an APL patient that gave rise to a new fusion gene, STRN3-RARA. STRN3 forms a complex called the stri...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE224816 Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia
Series Type : Genome binding/occupancy profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusHere we report a new fusion gene, STRN3-RARA, in acute promyelocytic leukemia (APL). It cooperates with UTX deficiency to drive full-blown APL in mice. Although STRN3-RARA leukemia quickly relapses after all-trans retinoic acid treatment, it can be restrained by cepharanthine. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Expression profiling by high throughput sequencing Homo sapiens Mus musculus Source Type: research
Cancers, Vol. 16, Pages 1614: Pharmacodynamic and Toxicity Studies of 6-Isopropyldithio-2 & prime;-Guanosine Analogs in Acute T-Lymphoblastic Leukemia
Conclusions: YLS010 has demonstrated specific killing effects against acute T-lymphoblastic leukemia both in vivo and in vitro. Preclinical studies of YLS010 offer a new opportunity for the treatment of patients with acute T-lymphoblastic leukemia in clinical settings. (Source: Cancers)
Source: Cancers - April 23, 2024 Category: Cancer & Oncology Authors: Tiantian Song Zheming Yu Qitao Shen Yu Xu Haihong Hu Junqing Liu Kui Zeng Jinxiu Lei Lushan Yu Tags: Article Source Type: research
